Immunicum AB (IMMU):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Immunicum AB (IMMU) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8207
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:64
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Immunicum AB (Immunicum) is a biopharmaceutical company that focuses on the development of immuno-oncology therapies for the treatment of solid tumors. The company’s lead development candidate, ilixadencel is in clinical trials for the treatment a range of solid tumors including hepatic cell carcinoma, renal cell carcinoma, and gastrointestinal stromal carcinoma; and for the treatment of kidney cancer, liver cancer and gastrointestinal stromal tumors. Its technology platform programs include COMBIG, SUBCUVAX, Ad5PTDf35 – Adenovirusvector and CD70, among others. Immunicum spans its expertise in the development of allogeneic and off-the-shelf cell-based therapies. The company works in partnership with various academia, biotech and pharmaceutical companies to develop and commercialize new therapeutics. Immunicum is headquartered in Gothenburg, Sweden.

Immunicum AB (IMMU) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Immunicum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Immunicum AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Immunicum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Immunicum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Immunicum AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Immunicum AB, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Immunicum Acquires Patent for Oncolytic Therapy from Virex for USD0.2 Million 11
Partnerships 12
Immunicum Enters into Agreement with Accelovance and Midwest Melanoma Partnership 12
Immunicum Enters into Research Agreement with Rutgers Cancer Institute 13
Equity Offering 14
Immunicum to Raise USD19.32 Million in Rights Offering of Shares 14
Immunicum Raises USD24.2 Million in Rights Offering of Shares 16
Immunicum Raises USD15.5 Million in Right Offering of Shares 18
Immunicum Raises USD6.8 Million in Rights Offering of Shares 20
Immunicum Raises USD8.66 Million in Private Placement of Shares 21
Immunicum Completes IPO 22
Immunicum Announces Private Placement Of Shares For US$1.3 Million 23
Immunicum AB – Key Competitors 24
Immunicum AB – Key Employees 25
Immunicum AB – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Aug 17, 2018: Immunicum announce interim report April – June 2018 27
May 04, 2018: Immunicum Interim report January – March 2018 29
Feb 16, 2018: Immunicum Reports Net Loss Of TSEK18,826 In Fourth Quarter Of 2017 31
Nov 17, 2017: Immunicum Interim Report Q3-Corporate Update and Outlook 33
Aug 18, 2017: Immunicum: Interim Report Q2 – Corporate Update and Outlook 35
May 19, 2017: Immunicum: Quarterly Report January-March 2017 37
Feb 17, 2017: Immunicum: Year-End Report 2016 (July 2016 – December 2016) 39
Corporate Communications 42
Sep 17, 2018: Immunicum names Pawel Kalinski and Inge Marie Svane to scientific advisory board 42
Mar 14, 2018: The Nomination Committee of Immunicum proposes Michael Oredsson as new Chairman of the Board 43
Jan 31, 2018: Immunicum Appoints Michaela Gertz As CFO 44
Product News 45
09/28/2017: Immunicum Announces Completion of HCC Phase I/II Clinical Study –Topline Safety and Immune Response Data Support Continued Development of Ilixadencel in Liver Cancer 45
08/15/2017: Immunicum Announces Last Patient Last Visit in the Ongoing Phase I/II Hepatocellular Carcinoma Study 47
06/20/2017: Immunicum Announces Publication in Journal for ImmunoTherapy of Cancer of Results Overview from Ilixadencel’s First Clinical Study in Metastatic Renal Cell Carcinoma 48
06/12/2017: Immunicum Announces Approval of the International Nonproprietary Name (INN) ilixadencel for INTUVAX 50
02/05/2018: Immunicum Presents Case Study of One Patient from Phase I/II HCC Trial at Cholangiocarcinoma Foundation Annual Conference 51
Product Approvals 52
Mar 20, 2018: Immunicum Announces ATMP Certificate Granted by EMA to Ilixadencel for Manufacturing Quality and Non-clinical Data 52
Clinical Trials 53
Apr 03, 2018: Immunicum Provides Update on Ilixadencel Clinical Development Program 53
Jan 08, 2018: Immunicum Announces Completion of Patient Recruitment for Phase II MERECA Trial 55
Nov 27, 2017: Immunicum Announces Positive Preliminary Results from Proof-of- Concept Animal Study Testing Combination of Ilixadencel and Checkpoint Inhibitors 56
Nov 10, 2017: Immunicum and Academic Collaborators Publish Preclinical Ilixadencel Mode of Action Data in Journal Oncoimmunology 57
Nov 07, 2017: Immunicum Presents Further Preclinical Ilixadencel Mode of Action Data at Annual SITC Meeting 58
Sep 21, 2017: Immunicum to Present Preclinical Data on Ilixadencel’s Mode of Action at the SITC Meeting in the US 59
Aug 17, 2017: Immunicum Completes Strategic Analysis and Defines Updated Clinical Development Plan for Ilixadencel 60
Aug 10, 2017: Immunicum Announces Enrollment of First United States Patient in the Ongoing Phase 2 MERECA Trial for Ilixadencel 61
Feb 14, 2017: Immunicum announces approval in France for its Clinical Trial Application for INTUVAX in metastatic renal cell carcinoma 62
Other Significant Developments 63
Dec 04, 2017: Immunicum Announces Report from the Extraordinary General Meeting on December 4, 2017 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64

List of Tables
Immunicum AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Immunicum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Immunicum AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Immunicum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Immunicum AB, Deals By Therapy Area, 2012 to YTD 2018 9
Immunicum AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Immunicum Acquires Patent for Oncolytic Therapy from Virex for USD0.2 Million 11
Immunicum Enters into Agreement with Accelovance and Midwest Melanoma Partnership 12
Immunicum Enters into Research Agreement with Rutgers Cancer Institute 13
Immunicum to Raise USD19.32 Million in Rights Offering of Shares 14
Immunicum Raises USD24.2 Million in Rights Offering of Shares 16
Immunicum Raises USD15.5 Million in Right Offering of Shares 18
Immunicum Raises USD6.8 Million in Rights Offering of Shares 20
Immunicum Raises USD8.66 Million in Private Placement of Shares 21
Immunicum Completes IPO 22
Immunicum Announces Private Placement Of Shares For US$1.3 Million 23
Immunicum AB, Key Competitors 24
Immunicum AB, Key Employees 25
Immunicum AB, Other Locations 26

List of Figures
Immunicum AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Immunicum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Immunicum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Immunicum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Immunicum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Immunicum AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Immunicum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Immunicum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Immunicum AB (IMMU):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Immunomedics Inc (IMMU):医療機器:M&Aディール及び事業提携情報
    Summary Immunomedics Inc (Immunomedics) is a clinical-stage bio-pharmaceutical company that researches, develops, manufactures and commercializes monoclonal antibody-based drugs for the treatment of cancer and autoimmune disorders. The company develops its candidates based on its proprietary technol …
  • Glodon Co Ltd (002410):企業の財務・戦略的SWOT分析
    Glodon Co Ltd (002410) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Airgas Inc-医療機器分野:企業M&A・提携分析
    Summary Airgas Inc (Airgas), a subsidiary of Air Liquide S.A., is a supplier of industrial, medical, specialty gases and related equipment. The company also provides welding equipment, safety products, ammonia products, refrigerants, nitrous oxide, atmospheric gases, carbon dioxide and dry ice, weld …
  • Kumagai Gumi Co., Ltd.:企業の戦略・SWOT・財務分析
    Kumagai Gumi Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Kumagai Gumi Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Sahara Energy Ltd (SAH):石油・ガス:M&Aディール及び事業提携情報
    Summary Sahara Energy Ltd (Sahara Energy) is an oil and gas exploration and development company that acquires, exploits, explores, and develops oil and natural gas reserves in Western Canada. The company evaluates oil and gas exploration properties in Canada. It plans on growing through the drill bi …
  • Finley Resources Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Finley Resources Inc (Finley) is an oil and gas company that owns, manages, operates and develops oil and gas properties. The company operates its oil and gas properties in the areas of Permian Basin, South Texas, East Texas, Mississippi, Barnett Shale, San Juan Basin, Alabama, Oklahoma and …
  • Nordea Bank AB:企業の戦略・SWOT・財務情報
    Nordea Bank AB - Strategy, SWOT and Corporate Finance Report Summary Nordea Bank AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • MedMira Inc (MIR):企業の財務・戦略的SWOT分析
    Summary MedMira Inc (MedMira) is a developer, manufacturer and marketer of rapid diagnostics and technology platforms. The company offers products in the areas of HIV, H. pylori, multiplex, syphilis, miriad rvf toolkit, and tissue and eye banks. MedMira offers Miriad RVF toolkit that facilitates the …
  • Independence Group NL:企業のM&A・事業提携・投資動向
    Independence Group NL - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Independence Group NL Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • NCsoft Corporation (036570):企業の財務・戦略的SWOT分析
    NCsoft Corporation (036570) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Firstsource Solutions Ltd (FSL):企業の財務・戦略的SWOT分析
    Firstsource Solutions Ltd (FSL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Inform Diagnostics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Inform Diagnostics Inc(Inform Diagnostics) formerly known as Miraca Life Sciences, a subsidiary of Miraca Holdings Inc, is an anatomic pathology laboratory that offers diagnostic services. The laboratory provides services in the areas of breast health, dermatology, gastroenterology, hematolo …
  • Hyundai Heavy Industries Co., Ltd.:企業の戦略・SWOT・財務情報
    Hyundai Heavy Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Hyundai Heavy Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Teleflex Incorporated:戦略・SWOT・企業財務分析
    Teleflex Incorporated - Strategy, SWOT and Corporate Finance Report Summary Teleflex Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • University of Texas MD Anderson Cancer Center:医療機器:M&Aディール及び事業提携情報
    Summary University of Texas MD Anderson Cancer Center (MD Anderson) is one of the leading cancer care centers in the US. It is one of the three original comprehensive cancer care centers designated by the National Cancer Act of 1971 in the US and is affiliated to University of Texas Health. MD Ander …
  • ZIOPHARM Oncology Inc (ZIOP):企業の財務・戦略的SWOT分析
    Summary Ziopharm Oncology Inc (Ziopharm), is a provider of next-generation immune therapies. The company offers Controlled IL-12 and t-cell therapy to fight blood cancers and solid tumors. Its Controlled IL-12 platform provides therapy for cold tumors by turning them hot by activating an immune resp …
  • Rockwell Automation Inc (ROK):石油・ガス:M&Aディール及び事業提携情報
    Summary Rockwell Automation Inc (Rockwell) is a provider of industrial automation power, control and information systems. The company offers connected components, midrange architecture system, asset and consultancy management; engineered packages and panels integration; front end engineering and des …
  • Industrija nafte dd (INA-R-A):石油・ガス:M&Aディール及び事業提携情報
    Summary Industrija nafte dd (INA) is an integrated energy company, which operates across the energy value chain from exploration and production to refining and marketing to retail. It has interests in offshore and onshore assets in Croatia, Egypt, and Angola. The company manages refineries in Rijeka …
  • Proteus Digital Health Inc:企業の戦略的SWOT分析
    Proteus Digital Health Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Global Investment House KPSC (GLOBAL):企業の財務・戦略的SWOT分析
    Global Investment House KPSC (GLOBAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆